| 000 | 00976 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250516172002.0 | ||
| 264 | 0 | _c20160423 | |
| 008 | 201604s 0 0 eng d | ||
| 022 | _a1750-192X | ||
| 024 | 7 |
_a10.2217/epi.13.53 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZarzour, Peter | |
| 245 | 0 | 0 |
_aEstablishing the clinical utility of epigenetic markers in cancer: many challenges ahead. _h[electronic resource] |
| 260 |
_bEpigenomics _c2013 |
||
| 300 |
_a513-23 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xgenetics |
| 650 | 0 | 4 | _aDNA Methylation |
| 650 | 0 | 4 | _aEpigenesis, Genetic |
| 650 | 0 | 4 | _aEpigenomics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeoplasms _xgenetics |
| 700 | 1 | _aHesson, Luke B | |
| 700 | 1 | _aWard, Robyn L | |
| 773 | 0 |
_tEpigenomics _gvol. 5 _gno. 5 _gp. 513-23 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2217/epi.13.53 _zAvailable from publisher's website |
| 999 |
_c23111085 _d23111085 |
||